This study is in progress, not accepting new patients

Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery

a study on Breast Cancer

Summary

Eligibility
for females ages 45 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Michael Alvarado
Headshot of Michael Alvarado
Michael Alvarado

Description

Summary

This phase IV trial studies the side effects of intraoperative radiation therapy and how well it works in treating patients with breast cancer undergoing breast-conserving surgery. Delivering radiation one time to the area where the tumor was removed while the patient is still in the operating room may kill any residual tumor cells and may be as effective as standard radiation therapy in patients with early stage breast cancer.

Official Title

Targeted Intraoperative Radiotherapy United States (TARGIT-US) Phase IV Registry Trial: A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery

Details

PRIMARY OBJECTIVES:

  1. To establish eligibility criteria based on previously published trials and studies in order to allow women who meet these criteria to receive intraoperative radiation therapy (IORT) on an Institutional Review Board (IRB)-approved protocol.

II. To systematically collect and assess acute and long-term toxicity and outcomes in larger cohort of patients.

III. To study the efficacy and toxicity of breast radiotherapy given intra-operatively as a single fraction after breast conserving surgery, with or without whole breast radiation, as indicated by pathologic risk factors, in women with early stage breast cancer.

IV. In-breast local failure and patterns of in-breast failure. V. Ipsilateral regional nodal failure. VI. Toxicity and morbidity. VII. Relapse-free survival. VIII. Overall survival.

OUTLINE:

Patients undergo IORT in a single fraction over 15-40 minutes at the time of standard of care lumpectomy.

After completion of study treatment, patients are followed up within 6 weeks and then every 6 months for 3 years and yearly for 2 years.

Keywords

Stage IA Breast Cancer, Stage IIA Breast Cancer, Breast Neoplasms, Intraoperative Radiation Therapy, Laboratory Biomarker Analysis

Eligibility

You can join if…

Open to females ages 45 years and up

  • Suitable for breast conserving surgery
  • T1 and T2 (< 3.5 cm), N0, M0

You CAN'T join if...

  • Axillary lymph node positive breast cancer
  • Tumor size > 3.5 cm
  • Extensive intraductal component (EIC >= 25% of the lumpectomy specimen involved with ductal carcinoma in situ), as assessed on surgical pathologic lumpectomy specimen
  • Multicentric cancer in the same breast as diagnosed by clinical examination, mammography, ultrasound; magnetic resonance imaging (MRI) or pathologic assessment, not amenable to excision with negative margins with a single lumpectomy
  • Inability to assess pathologic margin status
  • Synchronous bilateral breast cancer at the time of diagnosis
  • Ipsilateral breast had a previous cancer and/or prior in-field radiation
  • Patients known to have BRCA1/2 gene mutations (testing for gene mutations is not required)
  • Patients undergoing primary systemic treatment (hormones or chemotherapy) as initial treatment with neoadjuvant reducing tumor size
  • Previous history of malignant disease does not preclude entry if the expectation of relapse-free survival at 10 years or greater
  • Any factor included as exclusion criteria in the participating center's treatment policy statement
  • Additional exclusion criteria for University of California San Francisco (UCSF) (as laid out in the Treatment Policy):
    • Patients under the age of 50
    • Estrogen receptor negative (as defined in Treatment Policy under "Pathology")
    • Human epidermal growth factor receptor 2 (HER2) positive (as defined in Treatment Policy under "HER2")
    • Lymphovascular invasion
    • High grade
    • Tumors > 3 cm
    • Node positive patients
    • Prior chemotherapy or hormone therapy

Locations

  • UCSF
    San Francisco California 94143 United States
  • Alta Bates Summit Medical Center-Herrick Campus
    Berkeley California 94704 United States
  • John Muir Medical Center-Walnut Creek
    Walnut Creek California 94598 United States

Lead Scientist at UCSF

  • Michael Alvarado
    Dr. Michael Alvarado is a cancer surgeon who cares for patients with breast cancer and melanoma at the UCSF Helen Diller Family Comprehensive Cancer Center at Mount Zion. In his research, Alvarado conducts trials of radiation therapy for breast cancer. He also studies blood-based and molecular markers with the goal of improving breast cancer screening.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT01570998
Study Type
Interventional
Participants
About 1259 people participating
Last Updated